Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Thermo Fisher Scientific Inc.

Statement of Changes in Beneficial Ownership

Initial Statement of Beneficial Ownership

Insider	Title	Transaction Type	Shares Traded	% of Shares Traded	% Chg. in Shares	End of Filing Shares	Price	Transaction Value	Filing Date	Transaction Date
Marc N. Casper	Chairman, President & CEO, Independent Director Show All	Derivative Exercise and Sale (Sale)	-20K	-0.005235%	—	175.58K	$210.68 - $615.01	-$7.96M	05 Sep 2024	03 Sep 2024 - 04 Sep 2024
Frederick M. Lowery	Senior VP & President of Customer Channels, Independent Director Show All	Sale to Issuer (Sale)	-444	-0.000116%	-3.74%	11.42K	$613.14 - $613.14	-$272.15K	29 Aug 2024	28 Aug 2024 - 28 Aug 2024
Stephen Williamson	Senior VP & CFO Show All	Sale to Issuer (Sale)	-541	-0.000141%	-1.34%	39.97K	$613.14 - $613.14	-$331.73K	29 Aug 2024	28 Aug 2024 - 28 Aug 2024
Michael D. Shafer	Senior VP & President of Pharma Services Group Show All	Sale to Issuer (Sale)	-386	-0.000101%	-2.35%	16.08K	$613.14 - $613.14	-$236.87K	29 Aug 2024	28 Aug 2024 - 28 Aug 2024
Gianluca Pettiti	Executive Vice President Show All	Sale to Issuer (Sale)	-529	-0.000138%	-3.02%	16.96K	$613.14 - $613.14	-$324.32K	29 Aug 2024	28 Aug 2024 - 28 Aug 2024
Michel Lagarde
Joseph R. Holmes
Marc N. Casper
Lisa P. Britt
Michael A. Boxer
Gianluca Pettiti
Stephen Williamson
Michael D. Shafer
Frederick M. Lowery
Michel Lagarde
Joseph R. Holmes
Marc N. Casper
Lisa P. Britt
Michael A. Boxer
Marc N. Casper
Marc N. Casper
Gianluca Pettiti
Joseph R. Holmes
Lisa P. Britt
Michael A. Boxer
Scott M. Sperling
R. Alexandra Keith
Dion J. Weisler
Jennifer M. Johnson
Marc N. Casper